Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 February;60(1) > Minerva Cardioangiologica 2012 February;60(1):41-56

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

  INTERVENTIONAL CARDIOLOGY


Minerva Cardioangiologica 2012 February;60(1):41-56

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

New DES: a new step forward?

Ko B. S., Meredith I. T.

MonashHEART, Monash Cardiovascular Research Centre, Monash Medical Centre (MMC), Southern Health and Monash University, Melbourne, Australia


PDF  


Despite the benefits of first generation drug eluting stents (DES), concerns have been raised over their long term safety in particular the risk of stent thrombosis. As a result, the current generation and novel DES have been developed, the latter includes DES with biocompatible and biodegradable polymers, polymer free DES and completely bioresorbable stent platforms. Many of these stents are currently under evaluation in clinical trials, and early results are promising. This paper reviews the progress thus far in DES technology and aims to highlight the impact of recent DES innovations on clinical efficacy and safety.

top of page

Publication History

Cite this article as

Corresponding author e-mail

ian.meredith@myheart.id.au